Figure S1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Direct co-targeting of bcl-xl and mcl-1 increases efficacy in cancer models, enhancing treatment outcomes.
• The analysis reveals elevated levels of AR, AR-V7, and pro-survival proteins in multiple prostate cancer cell lines.
• Assessment employed protein level analysis across various prostate cancer cell lines to observe interactions.
• The findings highlight the importance of targeting both bcl-xl and mcl-1 for improving therapies in prostate cancer.